Payment overview · 2025
General Payments
$560.85
29 reported records · 12 companies
Healthcare provider profile · identity verified
Todd B Pearlstein, M.D,
Allopathic & Osteopathic Physicians|Family Medicine · TROY, AL · NPI 1821161837
Verified facts
What the public records show
CMS Open Payments records show Todd B Pearlstein, M.D, received $560.85 in general payments during 2025 across 29 reported records.
Phathom Pharmaceuticals, Inc. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Verquvo.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $120.42 | 21.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.70 | 13.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.08 | 10.9% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $56.57 | 10.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.44 | 9.2% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $40.69 | 7.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.81 | 5.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.09 | 5.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.58 | 5.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.13 | 5.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.71 | 3.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.63 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $560.85 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $120.42 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $56.57 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $51.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.48 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.69 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.09 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.39 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.13 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 126 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 130 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 180 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 219 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
126 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
180 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 15 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
219 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 606 | 182 |
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 176 |
| Pantoprazole Sodium | Pantoprazole Sodium | 417 | 133 |
| Losartan Potassium | Losartan Potassium | 320 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 88 |
| Metformin Hcl | Metformin Hcl | 279 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 82 |
| Gabapentin | Gabapentin | 224 | 58 |
| Ozempic | Semaglutide | 219 | 46 |
| Omeprazole | Omeprazole | 218 | 67 |
| Potassium Chloride | Potassium Chloride | 195 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 186 | 54 |
| Mounjaro | Tirzepatide | 180 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 57 |
| Ezetimibe | Ezetimibe | 173 | 60 |
| Lisinopril | Lisinopril | 173 | 48 |
| Tramadol Hcl | Tramadol Hcl | 173 | 40 |
| Carvedilol | Carvedilol | 162 | 45 |
| Sertraline Hcl | Sertraline Hcl | 155 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 51 |
| Trazodone Hcl | Trazodone Hcl | 150 | 45 |
| Alprazolam | Alprazolam | 147 | 42 |
| Jardiance | Empagliflozin | 130 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 24 |
| Eliquis | Apixaban | 126 | 34 |
| Clonazepam | Clonazepam | 115 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 114 | 30 |
| Meloxicam | Meloxicam | 113 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 32 |
| Celecoxib | Celecoxib | 106 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 38 |
| Simvastatin | Simvastatin | 103 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 29 |
| Furosemide | Furosemide | 88 | 30 |
| Ramipril | Ramipril | 86 | 25 |
| Trulicity | Dulaglutide | 79 | 15 |
| Chlorthalidone | Chlorthalidone | 77 | 25 |
| Donepezil Hcl | Donepezil Hcl | 77 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 24 |
| Synthroid | Levothyroxine Sodium | 73 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 26 |
| Pregabalin | Pregabalin | 70 | 19 |
| Allopurinol | Allopurinol | 66 | 25 |
| Xarelto | Rivaroxaban | 66 | 19 |
| Glimepiride | Glimepiride | 65 | 21 |
| Farxiga | Dapagliflozin Propanediol | 64 | 14 |
| Bupropion Xl | Bupropion Hcl | 62 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 16 |
| Fluconazole | Fluconazole | 59 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 18 |
| Telmisartan | Telmisartan | 56 | 18 |
| Fenofibrate | Fenofibrate | 50 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 16 |
| Montelukast Sodium | Montelukast Sodium | 50 | 20 |
| Famotidine | Famotidine | 49 | 21 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Valsartan | Valsartan | 49 | 15 |
| Finasteride | Finasteride | 47 | 16 |
| Indapamide | Indapamide | 46 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Linzess | Linaclotide | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 12 |
| Spironolactone | Spironolactone | 42 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 21 |
| Baclofen | Baclofen | 41 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 12 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Acarbose | Acarbose | 38 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Bumetanide | Bumetanide | 37 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 12 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | 13 |
| Ondansetron Odt | Ondansetron | 33 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 13 |
| Meclizine Hcl | Meclizine Hcl | 30 | 17 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Prednisone | Prednisone | 28 | 15 |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Estradiol | Estradiol | 26 | 12 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Colchicine | Colchicine | 23 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 23 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Cimetidine | Cimetidine | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Verquvo | Vericiguat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $560.85 · 29 records | Phathom Pharmaceuticals, Inc. | BREZTRI, CAMZYOS, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, MOUNJARO, Ozempic, PROLIA, QULIPTA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VOQUEZNA, Veozah, Wegovy, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error